Cargando…
Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions
BACKGROUND: COVID 19 infection caused by novel coronavirus with no specific established treatment. Convalescent Plasma Therapy has been authorized as an off-label therapeutic procedure. We assessed the outcome of convalescent plasma (CP) units versus standard treatment on the complete recovery, impr...
Autores principales: | Mahapatra, S., Rattan, R., Mohanty, C.B.K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132190/ https://www.ncbi.nlm.nih.gov/pubmed/33965621 http://dx.doi.org/10.1016/j.tracli.2021.04.009 |
Ejemplares similares
-
Convalescent plasma therapy in patients with COVID-19
por: Altuntas, Fevzi, et al.
Publicado: (2021) -
Convalescent plasma therapy in patients with COVID-19
por: Altuntas, Fevzi, et al.
Publicado: (2021) -
Convalescent plasma in the management of COVID-19 pneumonia
por: Elbadawi, Ayman, et al.
Publicado: (2021) -
Convalescent plasma therapy - a silver lining for COVID-19 management?
por: Saha, Sumit, et al.
Publicado: (2021) -
Challenges of Convalescent Plasma Therapy on COVID-19
por: Zhao, Qian, et al.
Publicado: (2020)